Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 4
1(33.3%)
3Total
Phase 2(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06840080Phase 4Completed

OEA and LipiSperse Metabolic Study

Role: collaborator

NCT07028528Phase 2Recruiting

Levagen+ Efficacy Study on Diabetic Peripheral Neuropathy

Role: collaborator

NCT02188251Phase 2Completed

A Study Investigating the Effects of Activamp on Body Weight, Fat Loss, and Metabolic Markers in Healthy Overweight Participants

Role: collaborator

All 3 trials loaded